GlassScriptPhysician profile
Imran Chowdhury
NPI 1396747549
$7,583.29
in general payments reported to CMS, 2019-2025
19 companies · $903 in 2025
The $903 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $651 · 2020: $969 · 2021: $1,807 · 2022: $1,368 · 2023: $1,228 · 2024: $657 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,788.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,666.02 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $1,314.25 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Abbvie INC. | $660.87 | 2021-2025 | Mavyret, Dalvance |
| Merck Sharp & Dohme LLC | $654.97 | 2019-2025 | Pifeltro, Dificid, Delstrigo |
| Melinta Therapeutics, LLC | $404.84 | 2020-2025 | Kimyrsa, Rezzayo |
| Paratek Pharmaceuticals, INC. | $297.12 | 2019-2025 | Nuzyra |
| Theratechnologies INC. | $237.83 | 2019-2023 | Egrifta, Trogarzo |
| Janssen Products, LP | $229.89 | 2021-2022 | |
| Shionogi INC | $210.90 | 2021-2025 | Fetroja |
| Cipla USA INC. | $194.26 | 2021 | |
| Janssen Biotech, INC. | $166.52 | 2019-2023 | Symtuza |
| Astellas Pharma US INC | $151.57 | 2020-2025 | Cresemba |
| Allergan, INC. | $96.16 | 2019-2020 | |
| Horizon Therapeutics Plc | $90.38 | 2020-2023 | Tepezza |
| Insmed, INC. | $68.90 | 2021-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $47.98 | 2024-2025 | Zenpep |
| Pfizer INC. | $39.75 | 2021-2023 | |
| La Jolla Pharmaceutical Company | $27.93 | 2024 | Xerava |
| Ferring Pharmaceuticals INC. | $23.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Chowdhury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.